Headline Details

Spark's price for Luxturna blindness gene therapy too high: ICER

Published on: Fri, 12 Jan 2018 20:33:57 UTC
News Agency: Reuters
Description:
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Click here for FULL Story on Reuters

Also happening now

HeadlineNews Agency
'A new history starts now' as North Korea's Kim meets South Korean leader Reuters
India's Modi to get museum tour, dinner with Xi as China trip begins Reuters
New Secretary of State Pompeo arrives in Brussels to meet NATO allies Reuters
'A new history starts now' as leaders of two Koreas meet Reuters
Migrants in caravan at U.S. border bide time ahead of crossing Reuters